A
Asceneuron
Biotech & Life Sciences · Lausanne, Switzerland · Founded 2012
Develops effective therapeutics for orphan tauopathies MoreLess
Asceneuron is an emerging biotech company focused on discovering and developing groundbreaking therapeutics for neurodegenerative disorders, particularly those with high unmet medical needs such as orphan tauopathies and other related diseases. The company operates in the biotechnology and pharmaceutical market, primarily serving patients suffering from central nervous system (CNS) disorders. Asceneuron's business model revolves around research and development (R&D) of innovative small molecules that have the potential to halt and prevent neurodegeneration. The company generates revenue through partnerships, grants, and potential future sales of its therapeutic products. Asceneuron's R&D pipeline is designed to address significant gaps in current treatment options, aiming to improve patients' lives by providing effective solutions for complex brain diseases. The company actively participates in industry conferences and collaborates with leading experts to stay at the forefront of CNS therapeutic development.
Keywords: neurodegenerative, therapeutics, CNS disorders, tauopathies, biotech, small molecules, R&D, brain diseases, innovative, partnerships.
Company overview
Asceneuron company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2012
- Headquarters
- Lausanne, Switzerland
- Employees
- 9
- Open positions
- None listed
- Dealroom signal
- 62.5
Valuation & funding
Asceneuron funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Jul 2024 | $100M | $400M | SR One · Johnson & Johnson Innovation · Sofinnova Partners · EQT Life Sciences | ↗ |
| GRANTOther financing | May 2022 | — | — | Michael J. Fox Foundation for Parkinson's Research | ↗ |
| GRANTOther financing | Oct 2016 | — | — | Michael J. Fox Foundation for Parkinson's Research | — |
| SERIES AOther financing | Sep 2015 | $30M | $119M | Kurma Partners · Sofinnova Partners · SR One · M Ventures | — |
| SPINOUTOther financing | Jan 2012 | $0 | — | Merck KGaA | ↗ |
Financials
Revenue and workforce over time
Available revenue and workforce history. Fields without reported data are omitted.
| Year | Revenue | Growth | Employees |
|---|---|---|---|
| 2026 | $4.9M | 0% | 9 |
| 2025 | $4.9M | 0% | 10 |
| 2024 | $4.9M | 0% | 20 |
| 2023 | $4.9M | 0% | 18 |
| 2022 | $4.9M | 0% | 18 |
| 2021 | $4.9M | 0% | 19 |
| 2020 | $4.9M | — | 19 |
Growth signals
Asceneuron website traffic
Latest recorded traffic for Asceneuron is 270 monthly website visits, down 79.2% over the last three months. Asceneuron's team declined 10% over the past year.
Comparisons
Asceneuron compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Asceneuron's talent
Source: Dealroom Talent Intelligence.
Investors
11 investors on Asceneuron's cap table
Sourced from Dealroom's funding and investor records. Investor profile links are shown where available.
Global footprint
Where Asceneuron has talent and traffic
team presence
In the news
Latest news about Asceneuron
Recent press, funding announcements, and product moves mentioning Asceneuron — open to read from the original sources.
Market sentiment
What the market is saying about Asceneuron
An AI-synthesized read of the highest-engagement posts about Asceneuron on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Asceneuron’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.